Gaceta Médica, leading newspaper in health information, interviews Dra. Isabel Portero, CEO & Founder of BIOHOPE

"Closer to the personalization of renal transplant treatment. First study to evaluate the functionality of the immunobiogram to predict the immunosuppressive response." > Read  More

2018-07-27T11:17:11+00:00July 26th, 2018|Clinical Development, Research|0 Comments

Different media publish the new of the success of the immunobiogram

Following the presentation of Biohope at the Congress of the International Society of Transplantation held in Madrid, the media have published different articles on the results of the clinical study that demonstrate the usefulness of the Immunobiogram. Diario medico 'Antibiogram of immunity' for rejection in kidney graft" >Read Article (pdf) Diario Médico.com > Read Article [...]

2018-07-18T16:06:22+00:00July 15th, 2018|Clinical Development, Research|0 Comments

BIOHOPE received the approval from the Ethics Committees for the TRANSBIO clinical study that will be developed in collaboration with 8 international hospitals

BIOHOPE recently received the approval of the TRANSBIO clinical study protocol and informed consents forms from the 8 Ethics Committees of the centres involved in the study. The study will be developed in collaboration with the University Hospital, Hospital del Mar and Hospital Vall’d Hebron (Barcelona, Spain); the Hospital Puerta de Hierro and Hospital La [...]

2018-05-28T16:55:25+00:00May 11th, 2018|Clinical Development|0 Comments

INMUNOBIOGRAM, Biohope’s test, facilitates the personalization of immunosuppressive treatment in patients with kidney transplantation

BIOHOPE recently presented the first data of their pilot study "BH-Pilot", at an investigator meeting with their Scientific Advisory Board held in the context of the European Society of Organ Transplantation (Barcelona, 24-27 September 2017). The study is being developed in collaboration with the Hospital Puerta de Hierro and La Paz University Hospital, both in [...]

2018-05-28T17:08:14+00:00October 3rd, 2017|Clinical Development|0 Comments